

Running head: SARS-CoV-2 screening considerations

27 January 2022

1 **Screening for SARS-CoV-2 in close contacts of individuals with confirmed**
2 **infection: performance and operational considerations**

3 Stephanie Zobrist^{1*#}, Michelle Oliveira-Silva^{2#}, Alexia Martines Vieira², Pooja Bansil¹, Emily Gerth-
4 Guyette¹, Brandon T. Leader¹, Allison Golden¹, Hannah Slater¹, Catherine Duran de Lucena Cruz²,
5 Eduardo Garbin², Mariana Sagalovsky¹, Sampa Pal¹, Vin Gupta³, Leo Wolansky⁴, Deusilene Souza Vieira
6 Dall'Acqua⁵, Felipe Gomes Naveca⁶, Valdinete Alves do Nascimento⁶, Juan Miguel Villalobos Salcedo⁵,
7 Paul K. Drain⁷, Alexandre Dias Tavares Costa⁸, Gonzalo J Domingo¹, Dhélio Pereira²

8 **Affiliations:**

- 9 1. Diagnostics, PATH, Seattle, Washington, United States
10 2. Centro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil
11 3. Amazon.com, Seattle, Washington, United States
12 4. The Rockefeller Foundation, Pandemic Prevention Institute, New York City, New York, United
13 States
14 5. Fundação Oswaldo Cruz (FIOCRUZ), Porto Velho, Rondônia, Brazil
15 6. Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Manaus,
16 Amazonas, Brazil
17 7. Departments of Global Health and Medicine, University of Washington, Seattle, Washington, United
18 States
19 8. Instituto Carlos Chagas (ICC), Fundação Oswaldo Cruz (FIOCRUZ), Curitiba, Paraná, Brazil

20 *Corresponding author. Stephanie Zobrist, Tel: 206-285-3500, Email: szobrist@path.org

21 #These authors contributed equally to this work.

22 **Running head:** SARS-CoV-2 screening considerations

Running head: SARS-CoV-2 screening considerations

27 January 2022

23 **Footnotes**

24 *Conflict of Interest Statement*

25 The authors declare no conflicts of interest.

26 *Funding Statement*

27 This study was funded by The Rockefeller Foundation and Amazon.com.

28 *Corresponding Author Contact Information*

29 Stephanie Zobrist

30 2201 Westlake Avenue, Suite 200

31 Seattle, WA, USA 98121

32 Tel: 206-285-3500

33 Email: szobrist@path.org

Running head: SARS-CoV-2 screening considerations

27 January 2022

34 **Abstract**

35 *Background.* Point-of-care and decentralized testing for SARS-CoV-2 is critical to inform public health
36 responses. Performance evaluations in priority use cases such as contact tracing can highlight trade-offs in
37 test selection and testing strategies.

38 *Methods.* A prospective diagnostic accuracy study was conducted among close contacts of COVID-19
39 cases in Brazil. Two anterior nares swabs (ANS), a nasopharyngeal swab (NPS), and saliva were
40 collected at all visits. Vaccination history and symptoms were assessed. Household contacts were
41 followed longitudinally. Three rapid antigen tests and one molecular method were evaluated for usability
42 and performance against reference RT-PCR on NPS.

43 *Results.* Fifty index cases and 214 contacts (64 household) were enrolled. Sixty-five contacts were RT-
44 PCR positive during at least one visit. Vaccination did not influence viral load. Gamma variants were
45 most prevalent; Delta emerged increasingly during implementation. Overall sensitivity of evaluated tests
46 ranged from 33%–76%. Performance was higher among symptomatic cases and cases with Ct<34 and
47 lower among oligo/asymptomatic cases. Assuming a 24-hour time-to-result for RT-PCR, the cumulative
48 sensitivity of an ANS rapid antigen test was >70% and almost 90% after four days.

49 *Conclusions.* The near immediate time-to-result for antigen tests significantly offsets lower analytical
50 sensitivity in settings where RT-PCR results are delayed or unavailable.

51 **Keywords:** Porto Velho, Rondônia, Allplex™ SARS-CoV-2 Assay, SalivaDirect, SD Biosensor

52 STANDARD Q COVID-19 Ag, LumiraDx SARS-CoV-2 Ag Test

Running head: SARS-CoV-2 screening considerations

27 January 2022

53 **Introduction**

54 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which causes COVID-19, has
55 significantly burdened health systems globally, with over 22 million confirmed cases in Brazil alone as of
56 2021 [1]. A key challenge of the pandemic response is access to appropriate diagnostic testing, which is
57 critical to inform public health strategies [2].

58 The reference standard for SARS-CoV-2 testing is RT-PCR. While accurate, this method has many
59 practical limitations, including cost, laboratory infrastructure requirements, and often invasive sampling.
60 RT-PCR testing is typically centralized, which can lead to delays in reporting results to patients. Such
61 delays have important public health implications, including increased risk for transmission during the
62 period before results are available [3,4]. Expanded access to decentralized and point-of-care (POC)
63 testing is essential to identify cases early and limit community transmission, particularly where RT-PCR
64 is unavailable.

65 Infected persons both with and without symptoms can transmit SARS-CoV-2 [5–7]. Due to the
66 significance of asymptomatic transmission [8], testing these populations is often recommended, including
67 close contacts of individuals with confirmed infection as part of contact tracing, testing, and isolation
68 strategies [9,10].

69 Multiple platforms have been developed to enable decentralized and POC SARS-CoV-2 testing [11]. In
70 particular, rapid antigen tests have garnered interest due to their lower cost, ease of use, and rapid
71 turnaround time for results (typically <30 minutes) [10, 12]. The World Health Organization (WHO)
72 advises that rapid antigen tests meeting minimum performance criteria can be employed in a range of use
73 cases, including for testing of asymptomatic contacts of cases [10]. Previous performance evaluations
74 have shown variability, with strongest performance among symptomatic individuals with high viral loads
75 in early stages of infection [11, 13–15]. Several studies have investigated test performance among
76 contacts of confirmed cases [16,17]; however, more data are needed to understand trade-offs in test

Running head: SARS-CoV-2 screening considerations

27 January 2022

77 selection and inform screening strategies regarding the timing and frequency of testing and performance
78 characteristics.

79 **Methods**

80 **Study design and population**

81 A prospective diagnostic accuracy study was conducted among close contacts of COVID-19-positive
82 index cases in Porto Velho, Brazil, between July and September 2021. Symptomatic adults within seven
83 days of symptom onset who tested positive on a rapid SARS-CoV-2 antigen test (STANDARD Q
84 COVID-19 Ag Nasal Test, SD Biosensor, Republic of Korea) were recruited as index cases. Close
85 contacts were identified through interviews administered at enrollment of the index case. Individuals 12
86 years of age or older who resided in Porto Velho were eligible for inclusion as close contacts if they met
87 one or more of Brazil's criteria within the investigation period of the index case (two days prior to
88 symptom onset to the time of the interview) (Supplementary Material A) [18]. Contacts with prior
89 positive COVID-19 test results within the past three months were not eligible. A subset of household
90 contacts (who shared a primary residence with the index case) had serial visits for clinical evaluations and
91 testing every other day over nine days.

92 **Tests evaluated**

93 This study evaluated four SARS-CoV-2 tests: the STANDARD Q COVID-19 Ag Nasal and Saliva tests,
94 the SARS-CoV-2 Ag Test (LumiraDx™ Limited, United Kingdom), and the SalivaDirect™ protocol
95 (Yale School of Public Health, United States). The STANDARD Q tests are rapid chromatographic
96 immunoassays for qualitative detection of antigens from SARS-CoV-2 in human nasal and saliva
97 specimens, respectively. The LumiraDx test is a microfluidic immunofluorescence assay for qualitative
98 detection of antigen in nasal specimens [19–24]. SalivaDirect is a dual-plexed RT-PCR method for
99 SARS-CoV-2 detection from minimally processed saliva [25,26].

Running head: SARS-CoV-2 screening considerations

27 January 2022

100 **Study procedures at the point of care**

101 At enrollment, information on participant demographics, health status, and medical history were
102 collected. Presence, duration, and severity of symptoms were assessed at all visits, and two paired anterior
103 nares swabs (ANS), one nasopharyngeal swab (NPS), and saliva were collected (Supplementary Material
104 B). One ANS was used to run the STANDARD Q COVID-19 Ag Nasal Test during the visit. All
105 specimens were then transferred to a laboratory where the remaining tests were performed.
106 For household contacts in the longitudinal sample, if the POC screening test was positive, only one
107 additional study visit occurred, during which NPS were not collected to minimize staff exposure.
108 Participants were considered lost to follow-up after two missed visits.

109 **Laboratory procedures**

110 The extracted ANS mixed with LumiraDx buffer was frozen within five hours of collection and thawed
111 before testing, no more than five days after freezing. The saliva sample was also frozen; aliquots were
112 thawed for testing with the STANDARD Q COVID-19 Ag Saliva Test (within five days of freezing) and
113 SalivaDirect. Evaluated tests were conducted per manufacturer instructions and by operators blinded to
114 close contact POC and reference results.

115 *Reference testing.* NPS were used for reference testing with the Allplex™ SARS-CoV-2 Assay (Seegene
116 Inc., Republic of Korea), a multiplex real-time PCR assay, on a CFX96 real-time PCR machine (Bio-Rad,
117 United States) [27]. Automated RNA extraction was conducted using the Loccus Extracta kit (Loccus,
118 Brazil). All SARS-CoV-2-positive specimens were repeated on the same assay for quantitative estimation
119 of viral load. Specimens with cycle threshold (Ct) values <30 underwent genomic sequencing
120 (Supplementary Material C). Staff conducting reference testing were blinded to other close contact test
121 results.

122 **Usability assessment**

Running head: SARS-CoV-2 screening considerations

27 January 2022

123 Study staff responsible for use of the antigen tests were invited to participate in a usability assessment. A
124 System Usability Scale (SUS) was employed, and an Ease of Use (EoU) questionnaire was adapted
125 [21,28] (Supplementary Material D). SUS scores above 68 were considered acceptable [29,30]. To
126 analyze data from the EoU questionnaire, a matrix was used to rank aspects of the products' usability as
127 "satisfactory," "average," or "unsatisfactory" (Supplementary Material E) [21].

128 **Sample size and statistical analysis**

129 The sample size targeted at least 50 contacts with a positive reference result, including at least 20
130 asymptomatic individuals, to meet US FDA Emergency Use Authorization requirements [31].

131 Participants with no symptoms at the time of sampling were classified as asymptomatic. Participants were
132 considered symptomatic if they presented with cough, shortness of breath, difficulty breathing, or at least
133 two of the following symptoms at the time of sampling: fever, chills, rigor, myalgia, headache, sore
134 throat, new olfactory or taste disorder [32]. Participants who presented with one or more mild symptoms
135 but did not fit the symptomatic case definition and reported no care seeking or changes to behavior were
136 considered oligosymptomatic.

137 Sensitivity, specificity, and positive and negative predictive values were calculated using standard
138 formulas and presented with 95% CIs. Samples for which both RT-PCR and evaluated test results were
139 available were included in the analysis. Using the longitudinal dataset, trade-offs between performance
140 and utility of the evaluated tests in terms of cumulative sensitivity at specified time points were assessed
141 as a function of time-to-results.

142 Data were collected and managed using REDCap electronic data capture tools hosted at the Institute of
143 Translational Health Sciences [33]. Statistical analyses were conducted using Stata 15.0 (StataCorp,
144 College Station, Texas, USA) and R 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

145 **Ethical considerations**

Running head: SARS-CoV-2 screening considerations

27 January 2022

146 WCG Institutional Review Board (1301165), the CEPEM ethics committee, and Brazil's National
147 Research Ethics Commission approved this study (44351421.0.0000.0011). Written informed consent
148 was obtained for all participants. Minors under 18 provided assent, and written informed consent was
149 obtained from parents/legal guardians.

150 **Results**

151 **Participant characteristics**

152 Fifty symptomatic COVID-19-positive index cases and 214 of their associated close contacts were
153 enrolled (Table 1). Sixty-four contacts shared a primary residence with an index case and were therefore
154 included in the longitudinal sample. Contacts ranged from ages 13 to 79. The majority of participants
155 across all groups were female. Sixty-five contacts (30%, 65/214) were SARS-CoV-2 positive by the
156 reference assay during at least one visit (Figure 1). For household contacts, positivity rates and symptom
157 status varied by visit. In total, 42 paired samples were collected at unique visits with oligo/asymptomatic
158 positive contacts, from 32 participants.

159 *Vaccination status*

160 Most participants were either partially (45%, 118/264) or fully (27%, 70/264) vaccinated at enrollment
161 (Table 1). No statistical difference was observed in viral loads between vaccinated and unvaccinated
162 individuals (Figure 2; Supplementary Material F, G).

163 *Sequencing*

164 Sequences were available for 84 positive samples: 68 Gamma (P.1, P.1.4, and P.1.7), and 16 Delta
165 (AY.36, AY.4, AY.43, AY.99.2), with seven total lineages. The Delta strain became more prevalent
166 among samples collected later in the study (Supplementary Material H).

167 **Diagnostic performance**

Running head: SARS-CoV-2 screening considerations

27 January 2022

168 The two POC ANS antigen tests demonstrated comparable performance, with overall sensitivity of 55.0%
169 for the STANDARD Q (95% CI 43.5%–66.2%) and 50.6% for LumiraDx (95% CI 39.1%–62.1%) (Table
170 2). Performance increased to >80% sensitivity for both tests among symptomatic cases but decreased to
171 <30% among oligo/asymptomatic cases. For specimens with Ct values less than 34, above which viral
172 viability is negligent and quantification is not as reliable [34,35], performance of both tests improved,
173 with sensitivities in the ranges of 90% and 60% for symptomatic and oligo/asymptomatic cases,
174 respectively.

175 The SalivaDirect PCR assay showed the highest overall performance at 75.9% sensitivity (95% CI
176 65.0%–84.9%), which increased to 90.0% (95% CI 78.2%–96.7%) among contacts with Ct<34. In all
177 scenarios, the rapid STANDARD Q Saliva Test had a sensitivity of <53%.

178 Figure 3 presents the viral load of positive specimens, stratified by results of the STANDARD Q Nasal
179 and Saliva tests. Overall, specimens with low viral loads were more likely to yield negative results;
180 however, misclassification of specimens with high viral loads was more common with the saliva test.

181 **Longitudinal analysis**

182 To investigate how test results changed over time, descriptive grid plots were generated for all household
183 contacts with a positive reference result at any timepoint (Supplementary Material I). Figure 4 includes
184 two examples of overall patterns in the dataset.

185 The time-to-positivity from days since enrollment for close contacts with a positive reference result
186 (Ct<34) at any timepoint was assessed by comparing the proportion of participants with positive results
187 by reference RT-PCR and a POC ANS antigen test (STANDARD Q Nasal) under different scenarios for
188 RT-PCR result turnaround time (Figure 5). Even with a relatively rapid RT-PCR result turnaround of 24
189 hours, >70% of contacts would have been identified by a POC test. At 48 hours, cumulative sensitivity is
190 80%, increasing to nearly 90% at four days.

191 **Usability**

Running head: SARS-CoV-2 screening considerations

27 January 2022

192 In total, 12 study staff completed the usability assessment. All three POC antigen tests were considered
193 easy to use and SUS scores were acceptable (>77) (Supplementary Material J).

194 **Discussion**

195 In this study, performances of three POC antigen tests (two ANS and one saliva) and one molecular saliva
196 assay were assessed among close contacts of COVID-19-positive index cases. All tests demonstrated
197 strongest performance among symptomatic cases—and particularly those with Ct<34. Performance
198 decreased among oligo/asymptomatic cases, which is consistent with results of prior studies [11,13] and
199 may indicate that the tests are best able to detect those most likely to be infectious [34,35]. However,
200 there is no universal Ct value cut-off-point that corresponds to infectivity, and the relationship between Ct
201 values and viral load varies by laboratory [11].

202 The SalivaDirect assay had the best performance, with sensitivity of up to 90% among contacts with
203 Ct<34. Although this assay uses a noninvasive sample type and a simplified procedure that minimizes
204 processing time and costs, infrastructure and training requirements still limit the feasibility of
205 implementing this test in many settings, with potential implications for time-to-results.

206 The saliva antigen test had the lowest overall performance, consistent with the findings of other
207 evaluations of POC saliva antigen tests [36,37]. One recent evaluation of this test reported an overall
208 sensitivity of 66.1%; however, the reference assay was conducted on saliva [38]. In this study, the test
209 was run on passively collected saliva. This may have impacted performance, as the manufacturer
210 recommends use of actively collected saliva with snorted nasal mucus.

211 The two POC ANS antigen tests—STANDARD Q Nasal and LumiraDx—demonstrated comparable
212 performance which was best among cases with Ct<34. Among symptomatic cases and those with Ct<34,
213 both tests met WHO performance criteria ($\geq 80\%$ sensitivity and $\geq 97\%$ specificity) [10]. Both tests were
214 also considered easy to use; however, the LumiraDx test requires use of an instrument.

Running head: SARS-CoV-2 screening considerations

27 January 2022

215 Overall, the observed positivity rate among close contacts (65/214, 30%) highlights the importance of
216 contact tracing and testing as a public health strategy [39]. The longitudinal data demonstrate the value of
217 serial testing (particularly for individuals with known exposures) and the practical benefits of timely
218 results [40, 41]. In this study, we show that in settings where RT-PCR is unavailable or where time-to-
219 results is >4 days, close to 90% of individuals with Ct<34 could benefit from an earlier result via a POC
220 test. Even in settings where RT-PCR results are available within 24 hours, cumulative sensitivity of a
221 POC test is >70%. With repeat serial testing over a period of 9 days, the cumulative sensitivity of a POC
222 ANS antigen test increases from 70% to near 90%. In many settings, limited RT-PCR testing capacity—
223 especially during high demand—can lead to delays in results. Immediate results can impact behavior of
224 potentially infectious individuals, encouraging earlier isolation and signaling where additional testing is
225 warranted [4]. The emergence of antiviral therapies—which are more effective the sooner they are
226 taken—further underscores the value of timely results.

227 **Limitations**

228 Limitations of the study include its modest sample size, reflected in the 95% CIs reported with
229 performance indicators. Further, the STANDARD Q Nasal and LumiraDx tests are among the best-in-
230 class commercial POC antigen tests. Other tests with lower performance may increase the risk of missing
231 infections against the benefit of identifying cases, to the extent that other strategies may be needed if RT-
232 PCR is unavailable. Lastly, future research should investigate implications of new variants on diagnostic
233 performance across sample types.

234 **Conclusion**

235 The near immediate time-to-result of rapid antigen tests is a significant benefit that offsets reduced
236 sensitivity by decreasing diagnostic delays and onward viral transmission. Here, we demonstrate that
237 POC ANS antigen tests for SARS-CoV-2 are easy to use and perform adequately to provide prompt,
238 actionable information to both the health system and individuals.

Running head: SARS-CoV-2 screening considerations

27 January 2022

239 **Funding**

240 This work was supported by grants from The Rockefeller Foundation [2020 HTH 039] and Amazon.com
241 [2D-04020007] to GJD. REDCap hosted at the Institute of Translational Health Sciences is supported by
242 the National Center For Advancing Translational Sciences of the National Institutes of Health under
243 Award Number UL1 TR002319. FGN and VAN were supported by the National Council for Scientific
244 and Technological Development [grant 403276/2020-9] and Inova Fiocruz/Fundação Oswaldo Cruz
245 [grant VPPCB-007-FIO-18-2-30 - Knowledge generation]. FGN is a CNPq fellow.

246 **Acknowledgements**

247 The authors would like to thank all study participants as well as the clinical and laboratory staff at
248 CEPEM involved with this study. We also thank SD Biosensor and LumiraDx for facilitating the
249 availability of their tests for this study. Finally, we also thank Amanda Tsang and Christine Waresak for
250 editorial support with the manuscript.

Running head: SARS-CoV-2 screening considerations

27 January 2022

251 **Tables**

252 **Table 1. Characteristics of study participants.**

Characteristic	Index cases (N=50)	Close contacts, non-household (N=150)	Close contacts, household (N=64)
Age			
Mean (SD)	40.1 (12.8)	38.4 (14.6)	34.7 (17.2)
Range	19–68	13–86	14–79
Sex*, n (%)			
Female	32 (64.0)	81 (54.0)	37 (57.8)
Male	18 (36.0)	69 (46.0)	27 (42.2)
Vaccination status**, n (%)			
Fully vaccinated	12 (24.0)	43 (28.7)	15 (23.4)
Partially vaccinated	24 (48.0)	69 (46.0)	25 (39.0)
Unvaccinated	14 (28.0)	38 (25.3)	24 (37.5)
Vaccine type, n (%)			
AstraZeneca	19 (52.8)	47 (42.0)	11 (27.5)
CoronaVac	9 (25.0)	28 (25.0)	10 (25.0)
Johnson & Johnson	2 (5.6)	4 (3.6)	0 (0)
Pfizer	6 (16.7)	33 (29.5)	19 (47.5)
Relationship to index case, n (%)			
Family (same household)	-	0 (0)	64 (100.0)
Family (other household)	-	45 (29.3)	-
Neighbor	-	7 (4.7)	-
Friend	-	49 (32.7)	-

Running head: SARS-CoV-2 screening considerations

27 January 2022

Coworker	-	41 (27.3)	-
Classmate	-	4 (2.7)	-
Other	-	4 (2.7)	-
Duration of estimated exposure, n (%)			
15 minutes to 1 hour	-	30 (20.0)	-
1 to 3 hours	-	41 (27.3)	-
3 to 8 hours	-	68 (45.3)	-
8+ hours	-	11 (7.4)	64 (100.0)
Location of exposure, n (%)			
Home	-	84 (56.0)	64 (100.0)
Work	-	47 (31.3)	-
Social setting	-	15 (10.0)	-
Other	-	4 (2.7)	-

253 * No statistical differences were observed by sex in any of the three groups, using a t-test.

254 ** Fully vaccinated classification indicates that a participant had received all required vaccine doses and was >14 days since

255 receipt of the last vaccine dose at enrollment.

256 **Table 2. Performance indicators for tests evaluated using nasopharyngeal RT-PCR as the reference standard. Performance is shown**
 257 **across all close contacts and those with PCR Ct values of less than 34.** Tests with black headers were run on anterior nares swabs, and tests
 258 with grey headers were run on saliva.

	All close contacts			Close contacts (Ct<34)		
	(Household and non-household)			(Household and non-household)		
	Overall	Symptomatic positive	Oligo/asymptomatic positive	Overall	Symptomatic positive	Oligo/asymptomatic positive
STANDARD Q Nasal, n	343	38	42	313	34	16
Sensitivity (95% CI)	55.0 (43.5–66.2)	84.2 (68.8–94.0)	28.5 (15.7–44.6)	84.0 (70.9–92.8)	91.2 (76.3–98.1)	68.8 (41.3–89.0)
Specificity (95% CI)	100.0 (98.6–100.0)	N/A	N/A	100.0 (98.6–100.0)	N/A	N/A
PPV (95% CI)	100.0 (92.0–100.0)	N/A	N/A	100.0 (91.6–100.0)	N/A	N/A
NPV (95% CI)	88.0 (83.7–91.4)	N/A	N/A	97.0 (94.3–98.7)	N/A	N/A
LumiraDx Nasal, n	345	37	42	315	33	16
Sensitivity (95% CI)	50.6 (39.1–62.1)	81.1 (64.8–92.0)	23.8 (12.1–39.5)	79.6 (65.7–89.8)	87.9 (71.8–96.6)	62.5 (35.4–84.8)
Specificity (95% CI)	100.0 (98.6–100.0)	N/A	N/A	100.0 (98.6–100.0)	N/A	N/A
PPV (95% CI)	100.0 (91.2–100.0)	N/A	N/A	100.0 (91.0–100.0)	N/A	N/A
NPV (95% CI)	87.2 (82.9–90.7)	N/A	N/A	96.4 (93.4–98.2)	N/A	N/A
STANDARD Q Saliva, n	340	38	42	310	34	16
Sensitivity (95% CI)	32.5 (22.4–43.9)	50.0 (33.4–66.6)	16.7 (7.0–31.4)	48.0 (33.7–62.6)	52.9 (35.1–70.2)	37.5 (15.2–64.5)
Specificity (95% CI)	98.8 (96.7–99.8)	N/A	N/A	98.8 (96.7–99.8)	N/A	N/A

Running head: SARS-CoV-2 screening considerations

27 January 2022

PPV (95% CI)	89.7 (72.6–97.8)	N/A	N/A	88.9 (70.8–97.6)	N/A	N/A
NPV (95% CI)	82.6 (78.0–86.7)	N/A	N/A	90.8 (86.8–93.9)	N/A	N/A
SalivaDirect RT-PCR, n	339	38	41	310	34	16
Sensitivity (95% CI)	75.9 (65.0–84.9)	89.5 (75.2–97.1)	63.4 (46.9–77.9)	90.0 (78.2–96.7)	94.1 (80.3–99.3)	81.3 (54.4–96.0)
Specificity (95% CI)	97.7 (95.0–99.1)	N/A	N/A	97.7 (95.0–99.1)	N/A	N/A
PPV (95% CI)	90.9 (81.3–96.6)	N/A	N/A	88.2 (76.1–95.6)	N/A	N/A
NPV (95% CI)	93.0 (89.3–95.8)	N/A	N/A	98.1 (95.6–99.4)	N/A	N/A

259

CI: confidence interval; Ct: cycle threshold; PPV: positive predictive value; NPV: negative predictive value; N/A: not applicable; RT-PCR: reverse transcription-polymerase chain reaction

Running head: SARS-CoV-2 screening considerations

27 January 2022

260 **References**

1. Ministry of Health Health Surveillance Secretariat. Special Epidemiological Bulletin: Coronavirus Disease COVID-19. 10 December 2021. Available at: https://www.gov.br/saude/pt-br/media/pdf/2021/dezembro/11/boletim_epidemiologico_covid_92_10dez21.pdf.
2. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. *Nat Rev Microbiol* **2021** ; 19(3):171-183. doi:10.1038/s41579-020-00461-z.
3. Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijkert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *Lancet Public Health* **2020** ; 5(8):e452-e459. doi:10.1016/S2468-2667(20)30157-2.
4. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv* **2021** ; 7(1):eabd5393. doi:10.1126/sciadv.abd5393.
5. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. *Proc Natl Acad Sci U S A* **2021** ; 118(34):e2109229118. doi:10.1073/pnas.2109229118.
6. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. *PLoS Med* **2020** ; 17(9):e1003346. doi:10.1371/journal.pmed.1003346.
7. Byambasuren O, Cardona M, Bell K, et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. *JAMMI* **2020** ; 5(4): 223–234. doi: 10.3138/jammi-2020-0030.
8. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission- a living systematic review. *Clin Microbiol Infect* **2021** ; 27(4): 511–519. doi: 10.1016/j.cmi.2021.01.011.

Running head: SARS-CoV-2 screening considerations

27 January 2022

9. Fiore VG, DeFelice N, Glicksberg BS, et al. Containment of COVID-19: Simulating the impact of different policies and testing capacities for contact tracing, testing, and isolation. *PLoS One* **2021** ; 16(3):e0247614. doi:10.1371/journal.pone.0247614.
10. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. Interim Guidance. 6 October 2021. Geneva; WHO. Available at: <https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays>.
11. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev* **2020** ; 8(8):CD013705. doi:10.1002/14651858.CD013705.
12. Drain P. Rapid diagnostic testing for SARS-CoV-2 [published online ahead of print, 2022 Jan 7]. *N Eng J Med* **2022**. doi:10.1056/NEJMcp2117115.
13. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis [published correction appears in *PLoS Med* **2021** Oct 13 ; 18(10):e1003825]. *PLoS Med* **2021** ; 18(8):e1003735. doi:10.1371/journal.pmed.1003735.
14. Boum Y, Fai KN, Nikolay B, et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study [published correction appears in *Lancet Infect Dis* **2021 Jun** ; 21(6):e148] [published correction appears in *Lancet Infect Dis*. **2021 Jul** ; 21(7):e182]. *Lancet Infect Dis* **2021** ; 21(8):1089-96. doi:10.1016/S1473-3099(21)00132-8.
15. Baro B, Rodo P, Ouchi D, et al. Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. *J Infect* **2021** ; 82(6):269 -275. doi: 10.1016/j.jinf.2021.04.009

Running head: SARS-CoV-2 screening considerations

27 January 2022

16. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. *Clin Microbiol Infect* **2021** ; 27(4):636.e1-636.e4.
doi:10.1016/j.cmi.2020.12.022.
17. Schuit E, Veldhuijzen IK, Venekamp RP, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. *BMJ* **2021** ; 374:n1676. doi:10.1136/bmj.n1676.
18. Ministry of Health. Epidemiological Surveillance Guide: Public Health Emergency of National Importance due to Coronavirus Disease 2019. Available at:
https://portalarquivos.saude.gov.br/images/af_gvs_coronavirus_6ago20_ajustes-finais-2.pdf.
19. Drain P, Sulaiman R, Hoppers M, Lindner NM, Lawson V, Ellis JE. Performance of the LumiraDx Microfluidic Immunofluorescence Point-of-Care SARS-CoV-2 Antigen Test in asymptomatic adults and children [published online ahead of print, 2021 Oct 20]. *Am J Clin Pathol* **2021** ; aqab173. doi:10.1093/ajcp/aqab173.
20. Kohmer N, Toptan T, Pallas C, et al. The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in vitro. *J Clin Med* **2021** ; 10(2):328.
doi:10.3390/jcm10020328.
21. Krüger LJ, Klein JAF, Tobian F, et al. Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2 [published online ahead of print, 2021 Aug 12]. *Infection* **2021** ; 1-12. doi:10.1007/s15010-021-01681-y.
22. Bianco G, Boattini M, Barbui AM, et al. Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection. *J Clin Virol* **2021** ; 139:104838.
doi:10.1016/j.jcv.2021.104838.

Running head: SARS-CoV-2 screening considerations

27 January 2022

23. Fekete T. In adults and children, a rapid POC antigen test for COVID-19 (LumiraDx) had $\geq 97\%$ sensitivity and specificity vs. RT-PCR. *Ann Intern Med* **2021** ; 174(7):JC82.
doi:10.7326/ACPJ202107200-082.
24. Karon BS, Donato LJ, Bridgeman AR, et al. Analytical sensitivity and specificity of four point of care rapid antigen diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital PCR, and a mass spectrometric antigen assay as comparator methods. *Clin Chem* **2021** ; 67(11):1545-1553. doi:10.1093/clinchem/hvab138.
25. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. *Med (N Y)* **2021** ; 2(3):263-280.e6.
doi:10.1016/j.medj.2020.12.010.
26. Rodríguez Flores SN, Rodríguez-Martínez LM, Reyes-Berrones BL, Fernández-Santos NA, Sierra-Moncada EJ, Rodríguez-Pérez MA. Comparison between a standard and SalivaDirect RNA extraction protocol for molecular diagnosis of SARS-CoV-2 using nasopharyngeal swab and saliva clinical samples. *Front Bioeng Biotechnol* **2021** ; 9:638902.
doi:10.3389/fbioe.2021.638902.
27. Freppel W, Merindol N, Rallu F, Bergevin M. Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex™ 2019-nCoV assay. *Virology* **2020** ; 17(1):196. doi: 10.1186/s12985-020-01468-x.
28. World Health Organization. Antigen detection rapid diagnostic tests for coronavirus disease 2019 (COVID-19): master protocol for monitored implementation. Version 1.0. Geneva: WHO, **25 November 2020**. Available at: <https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-diagnostic-test-implementation-proposals>.
29. Sauro, J. A practical guide to the System Usability Scale: Background, benchmarks, & best practices. Denver, CO: Measuring Usability LLC, **2011**.

Running head: SARS-CoV-2 screening considerations

27 January 2022

30. Bangor, A., Kortum, PT, & Miller, JT. (2008). An empirical evaluation of the System Usability Scale. *International Journal of Human-Computer Interaction* **2008** ; 24(6), 574–94.
<https://doi.org/10.1080/10447310802205776>.
31. United States Food and Drug Administration. Template for Developers of Antigen Tests. Available at: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>. Version October 26 2020. Accessed 24 November 2020.
32. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition. Available at: <https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020/>. Accessed 10 September 2021.
33. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support, *J Biomed Inform* **2009** ; Apr;42(2):377-81.
34. Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients. *Sci Rep* **2021** ; 11:22863.
35. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* **2020** ; 39:1059–61.
36. Yokota I, Sakurazawa T, Sugita J, et al. Performance of qualitative and quantitative antigen tests for SARS-CoV-2 using saliva. *Infect Dis Rep* **2021** ; 13(3):742-7. doi:10.3390/idr13030069.
37. Kritikos A, Caruana G, Brouillet R, et al. Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients: results of a prospective comparative trial (RESTART). *Microorganisms* **2021** ; 9(9):1910. doi:10.3390/microorganisms9091910.

Running head: SARS-CoV-2 screening considerations

27 January 2022

38. Igloi Z, Velzing J, Huisman R, et al. Clinical evaluation of the SD Biosensor saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients. *PLoS One* **2021** ; Dec 22;16(12):e0260894. doi:10.1371/journal.pone.0260894.
39. Chung S, Marlow S, Tobias N, et al. Lessons from countries implementing find, test, trace, isolation and support policies in the rapid response of the COVID-19 pandemic: a systematic review. *BMJ Open* **2021** ; 11(7):e047832. Doi: 10.1136/bmjopen-2020-047832.
40. Smith RL, Gibson LL, Martinez PP, et al. Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection. *J Infect Dis* **2021** ; 224(6). doi:10.1093/infdis/jiab337.
41. Revollo B, Blanco I, Soler P, et al. Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomized controlled trial. *Lancet Infect Dis* **2021** ; 21(10):P1365 – 1372. doi: 10.1016/S1473-3099(21)00268-1.

Figure 1. Status of study participants, by visit.




Figure 2. Viral load value relationships of study participants a) by infection category and b) by vaccination status.




Figure 3. Viral load value distributions across antigen tests among close contacts for a) the STANDARD Q Nasal Test and b) the STANDARD Q Saliva Test.





Figure 4. Descriptive plots for a subset of close contacts positive by the RT-PCR reference assay. Visit numbers are shown on the x-axis, and test results and symptom status are shown on the y-axis. Symptom status is presented independently of RT-PCR reference assay result.

a. A symptomatic individual with a low Ct value who tested positive by all assays at enrollment and met the stopping criteria upon the second visit.



b. An individual with no or mild symptoms whose reference positivity status fluctuated between visits, with high Ct values overall, and no positive point-of-care test results.

